Submitted Manuscript: Confidential

template updated: February 2022

#### 1

# 2 Title: Aggregated eosinophils characterize airway mucus properties

4	Authors: Yui Miyabe <sup>1,2</sup> , Mineyo Fukuchi <sup>1</sup> , Hiroki Tomizawa <sup>1,2</sup> , Yuka Nakamura <sup>1</sup> , Mitsutoshi
5	Jikei <sup>3</sup> , Yoshinori Matsuwaki <sup>4</sup> , Misaki Arima <sup>1</sup> , Yasunori Konno <sup>1</sup> , Yuki Moritoki <sup>1</sup> , Masahide
6	Takeda <sup>1</sup> , Naoya Tanabe <sup>5</sup> , Hiroshi Sima <sup>5</sup> , Yusuke Shiraishi <sup>5</sup> , Toyohiro Hirai <sup>5</sup> , Nobuo Ohta <sup>6</sup> ,
7	Junko Takahata <sup>7</sup> , Atsushi Matsubara <sup>7</sup> , Takechiyo Yamada <sup>2</sup> , Koichiro Asano <sup>8</sup> , Isao Miyairi <sup>9</sup> ,
8	Rossana C. N. Melo <sup>10</sup> , Peter F. Weller <sup>11</sup> , and Shigeharu Ueki <sup>1</sup> *
9	Affiliations:
10	<sup>1</sup> Department of General Internal Medicine and Clinical Laboratory Medicine, Akita
11	University Graduate School of Medicine; Akita, Akita 010-8543, Japan.
12	<sup>2</sup> Department of Otorhinolaryngology Head and Neck Surgery, Akita University Graduate
13	School of Medicine; Akita, Akita 010-8543, Japan.
14	<sup>3</sup> Department of Materials Science, Akita University Graduate School of Engineering
15	Science; Akita, Akita 010-8502, Japan.
16	<sup>4</sup> Matsuwaki Clinic Shinagawa; Shinagawa, Tokyo 141-0001, Japan.
17	<sup>5</sup> Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University;
18	Kyoto, Kyoto 606-8501, Japan.
19	<sup>6</sup> Department of Otolaryngology, Tohoku Medical and Pharmaceutical University; Sendai,
20	Miyagi 981-8558, Japan.

21	<sup>7</sup> Department of Otorhinolaryngology-Head and Neck Surgery, Hirosaki University
22	Graduate School of Medicine; Hirosaki, Aomori 036-8562, Japan.
23	<sup>8</sup> Division of Pulmonary Medicine, Department of Medicine, Tokai University School of
24	Medicine; Isehara, Kanagawa 259-1193, Japan.
25	<sup>9</sup> Department of Pediatrics, Hamamatsu University School of Medicine; Hamamatsu,
26	Shizuoka 431-3192, Japan.
27	<sup>10</sup> Laboratory of Cellular Biology, Department of Biology, Institute of Biological Sciences,
28	Federal University of Juiz de Fora, Juiz de Fora Campus; MG, 36036-900, Brazil.
29	<sup>11</sup> Divisions of Allergy and Inflammation and Infectious Diseases, Department of
30	Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School; Boston, MA, 02215,
31	USA.
32	
33	*Corresponding author. Shigeharu Ueki, MD, PhD, Department of General Internal Medicine and
34	Clinical Laboratory Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita
35	010-8543, Japan
36	Phone: +81-18-884-6209; Fax: +81-18-884-6209
37	Email: shigeh@hos.akita-u.ac.jp
38	
39	One Sentence Summary: Intraluminal accumulation and activation of eosinophils contribute to
40	the clinical properties of airway mucus and may serve as a therapeutic target.
41	Abstract: Uncontrolled airway mucus is associated with diverse diseases. We hypothesized that
42	the physical characteristics of infiltrating granulocytes themselves affect the clinical properties of

mucus. Surgically obtained nasal mucus from patients with eosinophilic chronic rhinosinusitis 43 (ECRS) and neutrophil-dominant non-eosinophilic chronic rhinosinusitis (non-ECRS) was 44 assessed in terms of computed tomography (CT) density, viscosity, water content, wettability, and 45 granulocyte-specific proteins. In an observational study, we found that nasal mucus from patients 46 with ECRS had significantly higher CT density, viscosity, dry weight, and hydrophobicity than 47 mucus from patients with non-ECRS. The levels of eosinophil-specific proteins in nasal mucus 48 correlated with its physical properties. When isolated human eosinophils and neutrophils were 49 stimulated to induce extracellular traps followed by aggregate formation, we found that cell 50 aggregates showed physical and pathological findings that closely resembled mucus. Co-treatment 51 with heparin (which slenderizes the structure of eosinophil extracellular traps) and DNase 52 efficiently induced a reduction in the viscosity and hydrophobicity of both eosinophil aggregates 53 and eosinophilic mucus. The present study highlights the pathogenesis of mucus stasis in 54 infiltrated granulocyte aggregates from a new perspective. The combination of DNase and heparin 55 might be a novel therapeutic modality against pathologic viscous eosinophilic mucus. 56

57

#### 58 Main Text:

#### 59 INTRODUCTION

Airway mucus has a role as a physical barrier to prevent the entry of external pathogens and contributes to the expulsion of foreign substances through mucociliary transport and maintenance of local humidity (*1*). However, abnormal production, hypercondensation, and decreased clearance of airway mucus can lead to airway obstruction and prolonged inflammation, thereby leading to a poor prognosis (*2*).

65	In bacterial infection, airway mucus contains abundant neutrophils that migrate into the
66	airways to eliminate pathogens through phagocytosis. These neutrophils also possess
67	anti-microbial capacity in the form of the release of sticky chromatin structures, i.e., neutrophil
68	extracellular traps (NETs). NETs serve as scaffolding for antimicrobial mediators such as histones
69	and granule proteins, and contribute to the entrapment of bacteria and other extracellular
70	pathogens (3). Abundant eosinophil extracellular traps (EETs) were also observed in patients with
71	diverse eosinophilic diseases (4, 5). These extracellular traps (ETs) are major components of
72	inflammatory cell-rich mucus, and contribute to its viscosity.
73	Interestingly, a clinical characteristic of eosinophil-dominant mucus, which is often
74	associated with type 2 inflammation, is that it shows high viscosity. For instance, eosinophilic
75	chronic rhinosinusitis (ECRS) is resistant to conservative treatments using antimicrobial therapies
76	or nebulizers, and frequently requires surgical intervention for mucus removal, which is in contrast
77	to infectious rhinosinusitis (6, 7). Luminal impaction due to viscous mucus is also observed in
78	other eosinophilic upper and lower airway diseases such as eosinophilic otitis media (5), allergic
79	fungal sinusitis (8), allergic bronchopulmonary aspergillosis (9-11), plastic bronchitis (12, 13),
80	and eosinophilic asthma (14-16). Eosinophilic airway mucus has been clinically recognized as
81	allergic mucin, eosinophilic mucin, and mucus plug, and its consistency has been described as
82	being like chewing gum, cottage cheese, axle grease, and peanut butter, which can be a clue to the
83	diagnosis (17-19). The clinical similarity of eosinophil-rich mucus in different airway diseases has
84	been previously discussed (20), although the precise mechanisms leading to its accumulation are
85	less well understood.

86 It is of paramount importance to elucidate the mechanisms and appropriate control of 87 mucus in muco-obstructive airway diseases. The objective of this study was to clarify the

88	contribution of granulocytes to the characteristics of pathological mucus. Using multiple
89	modalities including biophysical approaches, our results highlight the differences between
90	neutrophil- and eosinophil-rich mucus, and the contributions of aggregated extracellular
91	trap-producing granulocytes.

92

#### 93 **RESULTS**

#### 94 Eosinophilic mucus shows high CT density

95 Microscopically, mucus from patients with ECRS is characterized by the presence of abundant eosinophil accumulations, whereas that from non-ECRS patients is characterized by 96 97 neutrophil accumulations (Fig. 1A). First, we questioned whether, in addition to differences in 98 cellular composition, mucus density would also vary between ECRS and non-ECRS patients. In typical eosinophilic mucus, a unique radiological imaging presentation is high attenuation on 99 100 computed tomography (CT) (10, 21). Accordingly, as shown in Fig. 1B, the mucus in patients with 101 ECRS often shows a high CT attenuation area, unlike that in non-ECRS patients. Surgically obtained mucus was hyperconcentrated as shown by macroscopic images in Fig. 1C and Movie 102 S1. Mucus collected from patients with ECRS was typically highly viscoelastic and thicker than 103 104 that from patients with non-ECRS. We initially aimed to quantify the CT value of mucus on routine sinus CT imaging; however, mucosal thickening and mucus were indistinguishable. To 105 106 solve this problem, we conducted an observational study to collect mucus samples from patients with ECRS and non-ECRS who needed surgical treatment, and established ex-vivo CT imaging 107 (Fig. 1D, Fig. S1). The patient demographics are indicated in Table S1. As expected, the mean CT 108 109 value of mucus from patients with ECRS showed significantly higher x-ray attenuation than mucus from patients with non-ECRS (48.5  $\pm$  16.9 Hounsfield units [HU] vs 34.2  $\pm$  6.9 HU, 110

p<0.01, Fig. 1D). These results indicate the presence of radiographical differences between</li>
 eosinophil- and neutrophil-dominant mucus.

113

#### 114 Biophysical properties of mucus are associated with its CT density

Next, we assessed the rheological properties of mucus samples, measuring their shear 115 viscosity using a rotational viscometer (Fig. 2A). With the plate in contact with the mucus sample, 116 117 the shear viscosity was measured at different values of shear stress. As shown in Fig. 2B, the 118 mucus viscosity decreased when the shear rate increased, indicating a non-Newtonian shear-thinning pattern, as found in previous studies on airway mucus (22). As expected, higher 119 120 shear viscosities were obtained in the mucus from patients with ECRS than in that obtained from 121 patients with non-ECRS. A positive correlation between viscosity and CT values was also observed (Fig. 2C). Next, we assessed the dry weight of the mucus using a thermogravimetric 122 123 analyzer (TGA) (Fig. 2D). The weight reduction of ECRS mucus took a longer time than 124 non-ECRS mucus to reach a plateau when the mucus samples were concentrated by gradually 125 heating up to 100°C (Fig. 2E), indicating a higher polymer concentration. In a randomly selected sample (because of technical limitations) that we tested, the dry weight of mucus from patients 126 with ECRS was significantly higher than that of patients with non-ECRS ( $40.6 \pm 7.0\%$  vs  $19.4 \pm$ 127 128 6.2%, p<0.01), and positively correlated with the CT value (Fig. 2F). To further determine the wettability of the mucus, the air-dried mucus surface was analyzed with a static water contact 129 angle (Fig. 2G). The mucus from patients with ECRS showed significantly higher hydrophobicity 130 131 than that from patients with non-ECRS ( $75.5 \pm 18.3^{\circ}$  vs  $44.9 \pm 18.6^{\circ}$ , p<0.0001, Fig. 2H). The mucus-water contact angles and CT values were positively correlated (Fig. 2I). These results 132

indicated that the biophysical properties of the mucus were associated with its radiographicalfindings.

135

## 136 **Eosinophilic-specific protein contents correlate with the biophysical properties of mucus**

137	To determine whether the biophysical properties of the mucus were associated with the
138	eosinophils in it, we measured the concentrations of the eosinophil-specific proteins galectin-10
139	and eosinophil-derived neurotoxin (EDN). The concentrations of galectin-10 (Figure 3A) and
140	EDN (Figure 3B) were significantly higher in mucus from patients with ECRS than in that from
141	patients with non-ECRS (galectin-10, $0.26 \pm 0.06$ vs $0.008 \pm 0.005$ , p<0.01; EDN, $2.09 \pm 0.16$ vs
142	$1.25 \pm 0.12 \ \mu$ g/ml, p<0.001). In contrast, the concentration of neutrophil granule protein
143	myeloperoxidase (MPO) was significantly higher in mucus from patients with non-ECRS (0.11 $\pm$
144	$0.11 \text{ vs } 0.33 \pm 0.37 \ \mu\text{g/ml}, \text{p} < 0.05, \text{Figure 3C}).$
145	The correlations between these protein levels and the physical properties or CT values of
146	mucus were analyzed (Table 1). Shear viscosity was positively correlated with levels of
147	galectin-10 and EDN, dry weight was positively correlated with levels of galectin-10, contact
148	angle was positively correlated with levels of galectin-10 and EDN but negatively correlated with
149	MPO, and CT values were positively correlated with levels of galectin-10 and EDN. Taken

together, these results support the hypothesis that the increased eosinophils in mucus contribute to

151 its biophysical characteristics.

152

## 153 Aggregated ETosis cells mimic mucus properties

154	Unlike apoptosis, which is characterized by DNA fragmentation, activated eosinophils and
155	neutrophils undergo ETosis to release filamentous ETs (23, 24). To investigate the hypothesis that
156	ETotic granulocytes in the mucus are involved in its biophysical properties, isolated human
157	eosinophils and neutrophils were stimulated with phorbol 12-myristate 13-acetate (PMA) to
158	induce ETosis and were aggregated by shear-flow (Figure 4A) (25). The macroscopic appearance
159	of cell aggregates showed significant differences; eosinophil aggregates (aggEETs) showed a
160	yellow-brownish eraser-dust-like appearance, whereas neutrophil aggregates (aggNETs) showed a
161	white gel-like appearance (Figure 4B). These aggregates consisted of accumulated ETs and cell
162	debris (Fig. S2). The sections closely resembled clinical mucus (Fig. 4C).
163	The CT values of aggEETs were significantly higher than those of aggNETs (Figure 4D).
164	Of note, the viscosity of aggEETs was higher than that of aggNETs and comparable to that of
165	clinically obtained mucus from patients with ECRS (Figure 4E). In line with the mucus, the
166	rheological properties of aggregated cells indicated a non-Newtonian shear-thinning pattern. The
167	higher adhesion and viscosity of aggEETs were also confirmed using wall slip time-lapse images
168	( <b>Movie S2</b> ).
1 40	

169 The weight reduction rate of aggNETs measured using the TGA was larger than that of 170 aggEETs, and reached a plateau more quickly (Figure 4F). The final dry weight percentages of 171 aggEETs and aggNETs were 19.5%  $\pm$  5.7% and 8.0%  $\pm$  2.8% (p<0.01) respectively (**Fig. 4G**). The interactions between water and polymer molecules of aggEETs and aggNETs assessed by 172 173 differential scanning calorimetry (26) showed similar patterns (Fig. S3), indicating no difference in phase transition behavior and molecular mobility. The wettability assessed by the static water 174 175 contact angle revealed that aggEETs showed significantly higher hydrophobicity than aggNETs 176  $(82.4^{\circ} \pm 2.1^{\circ} \text{ vs } 54.1^{\circ} \pm 2.8^{\circ}, \text{ p} < 0.0001, \text{ Fig. 4H})$ . These results indicate that in terms of CT value,

viscosity, dry weight, and wettability, the aggEETs and aggNETs represented similar physical
 properties to eosinophil- and neutrophil-dominant mucus, respectively.

179

#### 180 Heparin enhances DNase-mediated EET degradation

EETs are composed of approximately 30-nm-diameter condensed chromatin structures and 181 are resistant to degradation by deoxyribonuclease 1 (DNase 1), having a longer half-life than NETs 182 183 (25, 27). As heparin has been reported to relax NETs (28, 29), we treated EETs with heparin and 184 studied their ultrastructure. Interestingly, scanning electron microscopy revealed that heparin had a thinning effect on EETs (Fig. 5A). Transmission electron microscopy also revealed that the 185 aggregated nucleosome structure of EETs was decreased after heparin treatment (Fig. 5B). 186 187 Heparin-treated EETs consisted of smooth fibers and a globular domain, similar to the previously 188 reported ultrastructure of NETs (3). The mean diameter of non-treated EETs was  $29.8 \pm 0.05 \,\mu m$ , 189 whereas that of heparin treated EETs was  $19.2 \pm 0.03 \ \mu m$  (Fig. 5C). The relaxation effect of 190 heparin on EETs was observed within 5 minutes and was concentration dependent (Fig. S4A). 191 These results indicate the disorganization of the chromatin structure, presumably through a 192 heparin and histone interaction (30). Indeed, the liquid phase interaction of histone and heparin was confirmed by the co-precipitation (Fig. S4B, C). Specifically, heparin-induced relaxation of 193 194 EETs was canceled in the presence of excess histone (Fig. S4D).

To test whether heparin enhanced the DNase-mediated EET degradation, EETs were treated with DNase with or without heparin, and the amount of free DNA in the supernatant was quantified. Heparin itself did not increase the EET degradation, whereas DNase-induced EET degradation was significantly increased in the presence of heparin (**Fig. 5D**). These data lead us to

199 propose that the heparin-histone interaction relaxed the chromatin structure to promote

- 200 DNase-mediated DNA degradation.
- 201

#### 202 Effect of heparin and DNase on aggEETs and mucus

As aggregated cells were a complex of accumulated EETs and cell debris, we next aimed to study the effect of heparin and DNase 1 on the biophysical properties of aggEETs and aggNETs. In the static condition, we noticed that aggEETs were significantly more resistant to DNase than aggNETs, keeping their structure and DNA contents for 18 hours (**Fig. S5A**). Heparin induced a "swelling" effect on the aggEET structure and enhanced the DNase-mediated DNA degradation (**Fig. 6A, Fig. S5B**).

209 The change in shear viscosity was studied by short (1 hour) exposure of aggEETs to DNase and heparin (Fig. 6B). Compared with the control, the most significant decrease in viscosity was 210 211 observed in the aggEETs co-treated with DNase and heparin. Regarding wettability, we found that 212 the contact angle of the aggEETs treated with DNase, but not those treated with heparin, was significantly less than that of the control. Among the groups, treatment with DNase and heparin 213 induced the most significant decrease in hydrophobicity (Fig. 6C). These results indicate that 214 aggregated DNA contributed to the hydrophobicity of aggEETs, leading to DNase-resistant 215 viscosity. 216

To extend our findings to clinical samples, we examined the effect of DNase and heparin on the viscosity and wettability of mucus from patients with ECRS. As expected, eosinophilic mucin treated with DNase and heparin showed reduced shear viscosity (**Fig. 7A**). Treatment with DNase or heparin alone did not affect the wettability of eosinophilic mucin, although co-treatment

with DNase and heparin significantly reduced the hydrophobicity (Fig. 7B). Collectively, these
 data indicate the therapeutic potential of heparin for facilitating DNase-induced enzymatic
 degradation of EETs.

224

#### 225 **DISCUSSION**

The current study identified that intraluminal accumulation and activation of granulocytes 226 227 contributes to the clinical properties of hyperconcentrated airway mucus and may serve as a 228 therapeutic target. Airway mucus is a complex mixture of the following components: 1) mucus glycoprotein (mucin) derived from airway epithelial goblet cells and submucosal glands; 2) 229 230 detached or migrated cell components and substances released from them; 3) serum-derived 231 proteins such as leached albumin; 4) pathogens such as bacteria and viruses; 5) dust; 6) 232 electrolytes; 7) substances associated with infection such as secretory IgA and other immunoglobulins, lactoferrin, lysozymes, and defensins (31). Of these components, studies on the 233 viscosity of mucus have largely focused on the hypersecretion of mucin and biological changes to 234 235 it, whereas recent evidence has revealed that granulocyte-derived ET polymers contribute to the physical characteristics of inflammatory mucus (32, 33). 236

Granulocytes are the front-line cells of innate immunity, have a short lifespan, and do not divide once they mature. They are produced in large numbers in the bone marrow and can rapidly accumulate at inflammatory sites from the blood circulation. Once entering the airways, activated granulocytes can capture pathogens by causing ETosis, and then kill them with cytotoxic protein-containing ETs (*34*). Unlike neutrophilic inflammation, the majority of eosinophilic airway diseases are caused by sterile allergic reactions and have pathological implications. Utilizing the granulocyte-rich mucus from patients with chronic rhinosinusitis and blood-derived

cells, our data indicated that the presence of aggregated ETotic eosinophils influences the
biophysical characteristics of mucus. The CT values of sinus mucus were directly related to the
presence of eosinophilic inflammation and its biophysical properties, supporting the utility of CT
values for diagnosis and pathological evaluation in clinical practice.

Fixed airway obstruction due to eosinophilic mucus is a hallmark phenomenon of diverse 248 eosinophilic upper and lower airway diseases. The water contact angle experiments indicated the 249 hydrophobic properties of eosinophil-dominant mucus. Biochemically, water is the most abundant 250 constituent in airway mucus, composing about 98% of it under normal conditions. When the water 251 content is below 90%–93%, mucus inhibits the motility of cilia, producing mucus stasis (35). In 252 253 the current study, the mucus from patients with ECRS and non-ECRS was highly dehydrated (59.4% and 80.6% water, respectively), far exceeding that required to inhibit mucociliary 254 clearance. Poor mucus clearance directly causes reduced quality of life for patients. For instance, 255 the presence of eosinophilic mucin is reported to be associated with recurrence after endoscopic 256 sinus surgery for chronic rhinosinusitis (7). Granule proteins, cytokines, histones, and other 257 alarmins released from inflammatory cells may cause epithelial damage and tissue remodeling 258 when they remain intraluminally localized, generating muco-inflammatory positive feedback 259 (35-37). 260

To study the effects of eosinophils and neutrophils on the biophysical properties of mucus, we utilized blood-derived granulocytes. Using ETotic cell aggregates, we were able to reproduce similar physical properties as those clinically observed in eosinophil- and neutrophil-dominant mucus. While the mechanisms of inflammation have been investigated using molecular and genetic approaches, we believe that our cell population-based approach provides a better understanding of the biophysical phenomena. Although the current study focused on the properties

of the mucus, a significant difference between hydrophilic aggNETs and hydrophobic aggEETs 267 might account for formation of pathological features of diseased tissue such as neutrophilic 268 abscess (38) and eosinophilic granuloma (39). Our results provide a strong argument for targeting 269 excess granulocyte accumulation and ET formation as causes of tissue dysfunction. 270 Aerosolized recombinant human DNase 1 (dornase alpha) is an established treatment for 271 patients with cystic fibrosis, where it promotes the hydrolysis of NETs in airway secretions (40, 272 273 41). EETs have a well-conserved chromatin structure and are more aggregated than NETs, resulting in greater stability against DNase (25, 42). The current study is the first demonstration of 274 the relaxing effect of heparin on EETs. Negatively charged heparin has a high affinity for 275 276 positively charged histones, and it can disorganize chromatin fiber by liberating histones (29, 43). Heparin has pleiotropic effects, such as preventing the cytotoxic effects of extracellular histone 277 (44) and eosinophil granule proteins (45, 46). Our data support the combined use of heparin and 278 279 DNase by inhalation, endoscopic injection, or irrigation, with the potential to remove EETs to decrease the viscosity and hydrophobicity of eosinophil-dominant mucus (Fig. 7C). This simple 280 mucus modification strategy could be a better approach than targeting the mucin hypersecretion 281 pathway, which is subject to adverse consequences (47). 282

Limitations of the current case-control study include the heterogeneity of chronic rhinosinusitis. In both ECRS and non-ECRS, chronic rhinosinusitis is classified according to the JESREC scoring system, although the pathogenesis is a mixture of inflammation by neutrophils and eosinophils in varying degrees (*48*). Nevertheless, the concentrations of eosinophil-specific galectin-10 and EDN in mucus were associated with their properties, suggesting the importance of eosinophil density. Considering the limitations of our experimental study, we could not exclude the possibility of the presence of EET-independent granulocyte viscosity. AggEETs and aggNETs

are composed of condensed cell debris including actin polymer, which may cause viscosity (22).
Since neutrophils contain abundant protease that may degrade organized proteins (25), it is
conceivable that neutrophil cell debris has a much more disintegrated structure. Other possibilities
include cytolytic eosinophil production of *de novo* polymers such as Charcot-Leyden crystals (49),
and amyloid-like aggregation of granule protein (4, 45, 50). The difference between neutrophil and
eosinophil debris may be related to pathological differences, and further investigation is
warranted.

In conclusion, our study revealed the characteristics of mucus and aggregated cells using radiographical, biophysical, pathological, and molecular approaches. The current study also highlights the utility of cell-population-based biophysical analysis. Intraluminal granulocyte accumulation and the activation of these granulocytes to form aggregated ETs are processes involved in the clinical features of mucus. The combination of DNase and heparin may be a promising therapeutic modality against highly viscous eosinophilic mucus.

303

#### 304 MATERIALS AND METHODS

## 305 Study design

This was a case-control study comparing the CT values and physical properties of clinically obtained sinus mucus from age- and gender-matched ECRS and non-ECRS patients (**Table S1**). The sample size was based on preliminary data from our laboratory. Sinus mucus was obtained from patients with non-ECRS and those with ECRS treated by routine endoscopic sinus surgery between February 2017 and July 2019. Samples were immediately frozen at  $-30^{\circ}$ C and shipped to Akita University on dry ice and stored at  $-80^{\circ}$ C. Patients with ECRS were diagnosed

312 according to the diagnostic criteria of the JESREC study score (51). This scoring system assesses unilateral or bilateral disease, the presence of nasal polyps, blood eosinophilia, and dominant 313 shadow of ethmoid sinuses on CT scans. For a definitive diagnosis of ECRS, a score of 11 or 314 higher and a mean number of 70 or higher infiltrated eosinophil counts in sectioned tissue in the 315 three densest areas of cell infiltration in high power fields (×400, hematoxylin-eosin staining) is 316 required. Patients who did not meet the diagnosis of ECRS were classified as non-ECRS. Patients 317 with an established immunodeficiency, coagulation disorder, diagnosis of classic allergic fungal 318 sinusitis, eosinophilic granulomatosis with polyangiitis, fungal sinusitis, or cystic fibrosis, and 319 320 those who were pregnant, were excluded from the study. All patients scheduled for surgery had previously failed to respond to adequate trials of conservative medical therapy administered to 321 control their symptoms. All patients were free of systemic steroids for at least two months prior to 322 surgery. Preoperative demographics and medical history including sex and age were obtained for 323 each patient. For the mucus studies, the experiments were conducted with the investigator blinded 324 to the details of the samples. 325

The purpose of the experimental study using mucus from patients with ECRS and cell aggregates separately dominated by neutrophils or eosinophils was to investigate the mechanism behind the highly viscous eosinophilic airway mucus with a view to developing a rationally designed treatment. For the cell-based studies, measurements were made over at least three experiments. All experiments were approved by the Akita University institutional review board, protocol approval No. 994, 1965. Written informed consent was obtained from all participants in accordance with the principles laid out in the Declaration of Helsinki.

333

## 334 Cell purification

335	Eosinophils were isolated from peripheral blood from medication-free donors using a
336	MACS <sup>TM</sup> system (Miltenyi Biotec, Bergisch Gladbach, Germany) with CD16-negative selection
337	(anti-CD16 antibody-conjugated microbeads, #130-045-701, Miltenyi Biotec), as described
338	previously (52, 53). The purity of the isolated eosinophils was $>98\%$ of nucleated cells and the
339	viability >99%. Neutrophils (>95% neutrophils, viability >98%) were obtained by positive
340	selection using the same system. The viability and purity of the cells were analyzed via trypan blue
341	exclusion.

342

#### 343 Ex vivo CT value measurement

344 Nasal mucus and cell aggregates were stored in microtubes and scanned three times using an Aquilion ONE CT scanner (Fig. S1, Cannon Medical Systems, Otawara, Japan). The scanning 345 parameters were 120 kVp, 240 mA, 0.5-s exposure time, and 350-mm field of view. The raw data 346 347 were reconstructed with an FC 21 kernel to generate 512×512 matrix images with 0.5-mm slice thickness ( $0.67 \times 0.67 \times 0.5$ -mm voxel resolution). Each voxel had a CT value that represented the 348 x-ray attenuation of a substance where 0 Hounsfield units (HU) is the attenuation of water 349 350  $(1g/cm^3)$  and -1000 HU is the attenuation of air  $(0 g/cm^3)$ . The microtubes were excluded from the obtained CT images by applying a cut-off CT threshold of -100 HU and the mucus was extracted. 351 352 The CT values of the mucus were measured on each of the three scans and then averaged. 353

# 354 **Preparation and characterization of ETosis cell aggregates**

Isolated neutrophils and eosinophils  $(10-100 \times 10^6 \text{ cells})$  were stimulated with phorbol 12-myristate 13-acetate (PMA; Sigma, 10 ng/ml) in 6-well flat-bottom tissue culture plates, in

357	0.3% bovine serum albumin (BSA) containing phenol red-free RPMI 1640. After 18 hours (>99%
358	cell death with ETosis), culture plates were shaken (600 minutes <sup>-1</sup> , 20 minutes) with an MS1 plate
359	shaker (IKA Works, Wilmington, NC) to induce aggregates. The aggregates were collected using
360	a cell scraper and tweezers. In some experiments, they were fixed in 10% formalin and embedded
361	in paraffin, followed by hematoxylin-eosin staining. For liquid phase stability, aggregates were
362	stained with SYTOX green (1:5000) and viewed by an inverted microscope (Eclipse TE300,
363	Nikon, Tokyo, Japan) equipped with a cooled color digital camera (Spot 1.3.0, Diagnostic
364	Instruments, Sterling Heights, MI) in conjunction with IP Lab image analysis software
365	(Scanalytics, Fairfax, VA). Additional characterization is provided in Fig. S2.
366	
367	Measurement of shear viscosity
507	
368	The rheological experiments were carried out using an MCR302 rotational rheometer
368 369	The rheological experiments were carried out using an MCR302 rotational rheometer (Anton Paar Japan, Tokyo, Japan) with a cone–plate system (CP25-2) for shear fixation.
368 369 370	The rheological experiments were carried out using an MCR302 rotational rheometer (Anton Paar Japan, Tokyo, Japan) with a cone–plate system (CP25-2) for shear fixation. Frequency sweep tests were performed from 0.1 and/s to 100 rad/s. The shear thinning behavior
368 369 370 371	The rheological experiments were carried out using an MCR302 rotational rheometer (Anton Paar Japan, Tokyo, Japan) with a cone-plate system (CP25-2) for shear fixation. Frequency sweep tests were performed from $0.1$ rad/s to $100$ rad/s. The shear thinning behavior of secretions and cell aggregates was characterized over a range of 0 to $100 \text{ s}^{-1}$ . The viscosity of
<ul> <li>368</li> <li>369</li> <li>370</li> <li>371</li> <li>372</li> </ul>	The rheological experiments were carried out using an MCR302 rotational rheometer (Anton Paar Japan, Tokyo, Japan) with a cone-plate system (CP25-2) for shear fixation. Frequency sweep tests were performed from $0.1 \square$ rad/s to $100 \square$ rad/s. The shear thinning behavior of secretions and cell aggregates was characterized over a range of 0 to $100 \text{ s}^{-1}$ . The viscosity of the sample against shear rate was measured. All rheology studies were performed at $36^{\circ}$ C. In some
<ul> <li>368</li> <li>369</li> <li>370</li> <li>371</li> <li>372</li> <li>373</li> </ul>	The rheological experiments were carried out using an MCR302 rotational rheometer (Anton Paar Japan, Tokyo, Japan) with a cone-plate system (CP25-2) for shear fixation. Frequency sweep tests were performed from $0.1 \square$ rad/s to $100 \square$ rad/s. The shear thinning behavior of secretions and cell aggregates was characterized over a range of 0 to $100 \text{ s}^{-1}$ . The viscosity of the sample against shear rate was measured. All rheology studies were performed at 36°C. In some experiments, the shear viscosity was also measured with added DNase 1 (40 U/ml, New England
<ul> <li>368</li> <li>369</li> <li>370</li> <li>371</li> <li>372</li> <li>373</li> <li>374</li> </ul>	The rheological experiments were carried out using an MCR302 rotational rheometer (Anton Paar Japan, Tokyo, Japan) with a cone–plate system (CP25-2) for shear fixation. Frequency sweep tests were performed from $0.1 \Box$ rad/s to $100 \Box$ rad/s. The shear thinning behavior of secretions and cell aggregates was characterized over a range of 0 to $100 \text{ s}^{-1}$ . The viscosity of the sample against shear rate was measured. All rheology studies were performed at $36^{\circ}$ C. In some experiments, the shear viscosity was also measured with added DNase 1 (40 U/ml, New England Biolabs, Ipswich, MA) and/or heparin (300 µg/ml, Sigma-Aldrich, St. Louis, MO). DNase and/or
<ul> <li>368</li> <li>369</li> <li>370</li> <li>371</li> <li>372</li> <li>373</li> <li>374</li> <li>375</li> </ul>	The rheological experiments were carried out using an MCR302 rotational rheometer (Anton Paar Japan, Tokyo, Japan) with a cone-plate system (CP25-2) for shear fixation. Frequency sweep tests were performed from $0.1$ rad/s to $100$ rad/s. The shear thinning behavior of secretions and cell aggregates was characterized over a range of 0 to $100 \text{ s}^{-1}$ . The viscosity of the sample against shear rate was measured. All rheology studies were performed at $36^{\circ}$ C. In some experiments, the shear viscosity was also measured with added DNase 1 (40 U/ml, New England Biolabs, Ipswich, MA) and/or heparin (300 µg/ml, Sigma-Aldrich, St. Louis, MO). DNase and/or heparin were added in sufficient quantities to soak the samples in the tubes and the tubes were
<ul> <li>368</li> <li>369</li> <li>370</li> <li>371</li> <li>372</li> <li>373</li> <li>374</li> <li>375</li> <li>376</li> </ul>	The rheological experiments were carried out using an MCR302 rotational rheometer (Anton Paar Japan, Tokyo, Japan) with a cone–plate system (CP25-2) for shear fixation. Frequency sweep tests were performed from $0.1 \Box$ rad/s to $100 \Box$ rad/s. The shear thinning behavior of secretions and cell aggregates was characterized over a range of 0 to $100 \text{ s}^{-1}$ . The viscosity of the sample against shear rate was measured. All rheology studies were performed at $36^{\circ}$ C. In some experiments, the shear viscosity was also measured with added DNase 1 (40 U/ml, New England Biolabs, Ipswich, MA) and/or heparin (300 µg/ml, Sigma-Aldrich, St. Louis, MO). DNase and/or heparin were added in sufficient quantities to soak the samples in the tubes and the tubes were incubated for one hour at $37^{\circ}$ C. Before measurement of the shear viscosity, 20 mg of each sample

## 379 Thermogravimetric analysis (TGA)

380	A sample of each of the cell aggregates or mucus (5 mg) was placed in an alumina crucible
381	and heated in a thermogravimetric analyzer (STA 7300, Hitachi High-Technologies, Tokyo,
382	Japan). Samples (originally at 25°C) were heated at a rate of 10°C/minute up to a maximum of
383	100°C and were maintained at this temperature for 30 minutes in a stream of dry nitrogen. The
384	percentage weight change was evaluated, and the final weight was considered as the dry weight.
385	
386	Water contact angle analysis
387	Mucus or cell aggregates were uniformly smeared onto a slide and dried in ambient air for
388	6 hours. For measurement of the contact angle, a 4- $\mu$ l water droplet was placed using a
389	manipulator and imaged using a digital camera 30 s after the release of the droplet. The contact
390	angle values of the droplets were recorded using the ImageJ contact angle plug-in
391	(https://imagej.nih.gov/ij/). In some experiments, we also measured the contact angle of samples
392	treated overnight with DNase 1 (40 U/ml) and/or heparin (300 $\mu$ g/ml, Sigma-Aldrich, St. Louis,
393	MO). Prepared samples were smeared onto a slide and the contact angle was measured as
394	described above.

395

## 396 Measurement of the levels of EDN, galectin-10, and MPO

Ten microliters of 0.1% dithiothreitol were added to 10-mg mucus samples, which were then stirred for 15 minutes before being quickly frozen in liquid nitrogen. The samples were crushed with a multi-bead shocker (Yasui Kikai, Osaka, Japan) at 250 bpm for 10 s and then with an ultrasonic crusher (Bioruptor, BM Equipment Co., Ltd. Tokyo, Japan). The supernatant was

403	NY)
403	Cloud-Clone Corn Katy TX MBL Aichi Janan: MPO: Enzo Life Sciences Inc Farmingdale
402	were measured using ELISA assay kits (EDN: 7630, MBL, Nagoya, Japan; galectin-10:
401	collected by centrifugation ( $10\ 000 \times$ g, $10\ minutes$ ). The levels of EDN, galectin-10, and MPO

405

## 406 Scanning electron microscopy (SEM)

407 Eosinophils were added to round coverslips in culture plates and stimulated with PMA (10 ng/ml) for 3 hours or more to induce EET formation, with or without heparin (300 µg/ml, 30 408 minutes). They were then immediately fixed in a mixture of freshly prepared aldehydes (1% 409 410 glutaraldehyde and 1% paraformaldehyde) in 0.1 M phosphate buffer (pH 7.4) for 1 hour at room 411 temperature and processed for SEM. Coverslip-adherent cells were postfixed with 1% osmium 412 tetroxide in water for 1 hour and dehydrated in an ascending ethanol series from 50% (vol/vol) to absolute ethanol (10 minutes per step). Cells were then critical point dried in carbon dioxide. 413 Coverslips were mounted on aluminum holders, sputtered with 5-nm gold, and analyzed in a 414 415 scanning electron microscope (Thermo Fisher Scientific FEI Quanta 3D FEG Dual Beam (SEM/FIB)], which enabled excellent high resolution surface imaging. 416

Qualitative analyses were performed on 70 electron micrographs (n=35 for each group) at
different magnifications. For quantitative analyses of EETs, a total of 20 electron micrographs
from cytolytic eosinophils showing EETs (10 from untreated and 10 from heparin-treated cells)
were analyzed at 80 000×. The diameters of 20 EET fibers randomly selected from each electron
micrograph were measured, with a total of 400 fibers being analyzed (n=200 fibers in each group).
The mean diameter of the EET fibers was then determined for each group.

423

## 424 Transmission electron microscopy (TEM)

425	Eosinophils were seeded on Aclar film (Nishin EM, Tokyo, Japan), stimulated with 10
426	ng/ml of PMA for 3 hours, and then immediately fixed in a mixture of freshly prepared aldehydes
427	(1.25% glutaraldehyde and 1% paraformaldehyde) in 0.1 M cacodylate buffer. After incubation
428	for 2 hours in 0.1 M cacodylate buffer containing 1% OsO4, the specimens were dehydrated in an
429	ethanol series, passed through propylene oxide, and embedded in epoxy resin. Ultrathin sections
430	(80 nm) were collected on copper grids and stained for 20 minutes in 4% uranyl acetate and 0.5%
431	lead citrate. The specimens were viewed with a Hitachi H-7650 transmission electron microscope
432	at 100 kV.

433

## 434 **EET and aggEET dissolution assays**

Isolated eosinophils were induced to ETosis by stimulation with PMA (10 ng/ml) for 18 435 hours. The medium was replaced with 100  $\mu$ l of Ca<sup>2+</sup>-containing Hank's balanced salt solution 436 with Picogreen (Thermo Fisher Scientific, Waltham, MA, 1:100) and incubated with or without 437 DNase 1 (20 U/ml) and heparin (5 mg/ml). The plate was shaken gently (400 rpm) for 5 minutes at 438 room temperature. After pipetting, 100  $\mu$ l of medium was aspirated and centrifuged (500 $\times$  g, 5 439 minutes). The fluorescence intensity of the supernatant was immediately measured to quantify the 440 free DNA using a GloMax-Multi detection system (Promega, Madison, WI). In the static 441 condition, aggEETs were incubated at 37°C (0.3% BSA/RPMI medium) in the presence of DNase 442 1 (40 U/ml). To visualize DNA, SYTOX was added to the medium. Fluorescent images were 443

- obtained at indicated time points under an inverted microscope (Eclipse TE300, Nikon, Tokyo,
- 445 Japan) equipped with a cooled color digital camera.

446

# 447 Statistical Analysis

448	Results are expressed as mean $\pm$ SD. The data analysis in this study was performed using
449	GraphPad Prism software, Version 7 (GraphPad, San Diego, USA). The Wilcoxon signed rank test
450	or Welch's t test were used to evaluate differences between two groups. Multiple comparison tests
451	were used to compare means between groups. Correlation analysis was performed using
452	Spearman's rank correlation. A <i>p</i> -value of <0.05 was considered statistically significant.
453	
454	List of Supplementary Materials
455	Fig. S1. Computed tomography (CT) imaging of mucus and cell aggregate samples
456	Fig. S2. Structures of aggregated eosinophil extracellular traps (aggEETs) and aggregated
457	neutrophil extracellular traps (aggNETs)
458	Fig. S3. Differential scanning calorimetry (DSC) chart of aggEETs and aggNETs
459	Fig. S4. Heparin-induced relaxation ability on EETs
460	Fig. S5. Stability of aggEETs and aggNETs against DNase
461	Table S1. Clinical characteristics of patients with eosinophilic chronic rhinosinusitis (ECRS) and
462	non-eosinophilic chronic rhinosinusitis (non-ECRS).
463	Movie S1. Surgical removal of sinus mucus
464	Movie S2. Wall slip time-lapse images

465

#### **References and Notes** 466

467	1.	J. Widdicombe, Relationships among the composition of mucus, epithelial lining liquid,
468		and adhesion of microorganisms. Am. J. Respir. Crit. Care Med. 151, 2088-2092;
469		discussion 2092-2083 (1995).
470	2.	J. C. Hogg, F. S. F. Chu, W. C. Tan, D. D. Sin, S. A. Patel, P. D. Pare, F. J. Martinez, R. M.
471		Rogers, B. J. Make, G. J. Criner, R. M. Cherniack, A. Sharafkhaneh, J. D. Luketich, H. O.
472		Coxson, W. M. Elliott, F. C. Sciurba, Survival after Lung Volume Reduction in Chronic
473		Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 176, 454-459 (2007).
474	3.	V. Brinkmann, U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D. S. Weiss, Y.
475		Weinrauch, A. Zychlinsky, Neutrophil extracellular traps kill bacteria. <i>Science</i> <b>303</b> ,
476		1532-1535 (2004).
477	4.	S. Ueki, R. C. N. Melo, I. Ghiran, L. A. Spencer, A. M. Dvorak, P. F. Weller, Eosinophil
478		extracellular DNA trap cell death mediates lytic release of free secretion-competent
479		eosinophil granules in humans. <i>Blood</i> <b>121</b> , 2074-2083 (2013).
480	5.	N. Ohta, S. Ueki, Y. Konno, M. Hirokawa, T. Kubota, S. Tomioka-Matsutani, T. Suzuki,
481		Y. Ishida, T. Kawano, T. Miyasaka, T. Takahashi, T. Suzuki, I. Ohno, S. Kakehata, S.
482		Fujieda, ETosis-derived DNA trap production in middle ear effusion is a common feature
483		of eosinophilic otitis media. Allergol Int 67, 414-416 (2018).
484	6.	R. G. Slavin, Sinusitis: viral, bacterial, or fungal and what is the role of Staph? Allergy
485		Asthma Proc. 27, 447-450 (2006).
486	7.	S. Vlaminck, T. Vauterin, P. W. Hellings, M. Jorissen, F. Acke, P. Van Cauwenberge, C.
487		Bachert, P. Gevaert, The importance of local eosinophilia in the surgical outcome of
488		chronic rhinosinusitis: a 3-year prospective observational study. Am J Rhinol Allergy 28,
489		260-264 (2014).
490	8.	J. P. Bent, 3rd, F. A. Kuhn, Diagnosis of allergic fungal sinusitis. Otolaryngol. Head Neck
491		<i>Surg.</i> <b>111</b> , 580-588 (1994).
492	9.	S. Ueki, A. Hebisawa, M. Kitani, K. Asano, J. S. Neves, Allergic Bronchopulmonary
493		Aspergillosis–A Luminal Hypereosinophilic Disease With Extracellular Trap Cell Death.
494		<i>Front. Immunol.</i> <b>9</b> , 2346 (2018).
495	10.	R. Goyal, C. S. White, P. A. Templeton, E. J. Britt, L. J. Rubin, High attenuation mucous
496		plugs in allergic bronchopulmonary aspergillosis: CT appearance. J. Comput. Assist.
497		<i>Tomogr.</i> <b>16</b> , 649-650 (1992).
498	11.	P. M. Logan, N. L. Müller, High-attenuation mucous plugging in allergic
499		bronchopulmonary aspergillosis. Can. Assoc. Radiol. J. 47, 374-377 (1996).
500	12.	K. Ikari, J. Tezuka, T. Matsumoto, M. Tsuji, M. Kawamura, T. Oda, S. Ueki,
501		Charcot–Leyden Crystals in Rapidly Progressing Plastic Bronchitis. Am. J. Respir. Crit.
502		<i>Care Med.</i> <b>204</b> , e54-e55 (2021).
503	13.	M. Yoshida, Y. Miyahara, K. Orimo, N. Kono, M. Narita, Y. Ohya, K. Matsumoto, S.
504		Nakagawa, S. Ueki, H. Morita, I. Miyairi, Eosinophil Extracellular Traps in the Casts of
505		Plastic Bronchitis Associated With Influenza Virus Infection. Chest 160, 854-857 (2021).
506	14.	L. M. Kuyper, P. D. Pare, J. C. Hogg, R. K. Lambert, D. Ionescu, R. Woods, T. R. Bai,
507		Characterization of airway plugging in fatal asthma. Am. J. Med. 115, 6-11 (2003).

508	15.	W. V. Filley, K. E. Holley, G. M. Kephart, G. J. Gleich, Identification by
509		immunofluorescence of eosinophil granule major basic protein in lung tissues of patients
510		with bronchial asthma. Lancet 2, 11-16 (1982).
511	16.	S. Svenningsen, E. Haider, C. Boylan, M. Mukherjee, R. L. Eddy, D. P. I. Capaldi, G.
512		Parraga, P. Nair, CT and Functional MRI to Evaluate Airway Mucus in Severe Asthma.
513		<i>Chest</i> <b>155</b> , 1178-1189 (2019).
514	17.	S. Ueki, T. Tokunaga, S. Fujieda, K. Honda, M. Hirokawa, L. A. Spencer, P. F. Weller,
515		Eosinophil ETosis and DNA Traps: a New Look at Eosinophilic Inflammation. Curr.
516		Allergy Asthma Rep. 16, 54 (2016).
517	18.	W. J. Fokkens, V. J. Lund, C. Hopkins, P. W. Hellings, R. Kern, S. Reitsma, S.
518		Toppila-Salmi, M. Bernal-Sprekelsen, J. Mullol, I. Alobid, W. Terezinha Anselmo-Lima,
519		C. Bachert, F. Baroody, C. Von Buchwald, A. Cervin, N. Cohen, J. Constantinidis, L. De
520		Gabory, M. Desrosiers, Z. Diamant, R. G. Douglas, P. H. Gevaert, A. Hafner, R. J. Harvey,
521		G. F. Joos, L. Kalogjera, A. Knill, J. H. Kocks, B. N. Landis, J. Limpens, S. Lebeer, O.
522		Lourenco, P. M. Matricardi, C. Meco, L. O'Mahony, C. M. Philpott, D. Ryan, R.
523		Schlosser, B. Senior, T. L. Smith, T. Teeling, P. V. Tomazic, D. Y. Wang, D. Wang, L.
524		Zhang, A. M. Agius, C. Ahlstrom-Emanuelsson, R. Alabri, S. Albu, S. Alhabash, A.
525		Aleksic, M. Aloulah, M. Al-Qudah, S. Alsaleh, M. A. Baban, T. Baudoin, T. Balvers, P.
526		Battaglia, J. D. Bedoya, A. Beule, K. M. Bofares, I. Braverman, E. Brozek-Madry, B.
527		Richard, C. Callejas, S. Carrie, L. Caulley, D. Chussi, E. de Corso, A. Coste, L. Devyani,
528		U. El Hadi, A. Elfarouk, P. H. Eloy, S. Farrokhi, G. Felisati, M. D. Ferrari, R. Fishchuk, J.
529		W. Grayson, P. M. Goncalves, B. Grdinic, V. Grgic, A. W. Hamizan, J. V. Heinichen, S.
530		Husain, T. I. Ping, J. Ivaska, F. Jakimovska, L. Jovancevic, E. Kakande, R. Kamel, S.
531		Karpischenko, H. H. Kariyawasam, A. Kjeldsen, L. Klimek, S. W. Kim, J. J. Letort, A.
532		Lopatin, A. Mahdjoubi, J. Netkovski, D. N. Tshipukane, A. Obando-Valverde, M. Okano,
533		M. Onerci, Y. K. Ong, R. Orlandi, K. Ouennoughy, M. Ozkan, A. Peric, J. Plzak, E.
534		Prokopakis, N. Prepageran, A. Psaltis, B. Pugin, M. Raftopulos, P. Rombaux, S. Sahtout,
535		C. C. Sarafoleanu, K. Searyoh, C. S. Rhee, J. Shi, M. Shkoukani, A. K. Shukuryan, M.
536		Sicak, D. Smyth, K. Snidvongs, T. S. Kosak, P. Stjarne, B. Sutikno, S. Steinsvag, P.
537		Tantilipikorn, S. Thanaviratananich, T. Tran, J. Urbancic, A. Valiulis, C. V. De Aparicio,
538		D. Vicheva, P. M. Virkkula, G. Vicente, R. Voegels, M. M. Wagenmann, R. S. Wardani,
539		A. Welge-Lussen, I. Witterick, E. Wright, D. Zabolotniy, B. Zsolt, C. P. Zwetsloot,
540		European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology journal 0,
541		1-464 (2020).
542	19.	J. W. Grayson, M. Cavada, R. J. Harvey, Clinically relevant phenotypes in chronic
543		rhinosinusitis. J. Otolaryngol Head Neck Surg. 48, 23 (2019).
544	20.	T. S. Panchabhai, S. Mukhopadhyay, S. Sehgal, D. Bandyopadhyay, S. C. Erzurum, A. C.
545		Mehta, Plugs of the Air Passages: A Clinicopathologic Review. Chest 150, 1141-1157
546		(2016).
547	21.	W. P. Dillon, P. M. Som, G. D. Fullerton, Hypointense MR signal in chronically
548		inspissated sinonasal secretions. Radiology 174, 73-78 (1990).
549	22.	S. K. Lai, Y. Y. Wang, D. Wirtz, J. Hanes, Micro- and macrorheology of mucus. Adv Drug
550		<i>Deliv Rev</i> <b>61</b> , 86-100 (2009).
551	23.	V. H. Neves, C. Palazzi, K. Bonjour, S. Ueki, P. F. Weller, R. C. N. Melo, In Vivo ETosis
552		of Human Eosinophils: The Ultrastructural Signature Captured by TEM in Eosinophilic
553		Diseases. Front. Immunol. 13, 938691 (2022).

24. M. Fukuchi, Y. Miyabe, C. Furutani, T. Saga, Y. Moritoki, T. Yamada, P. F. Weller, S. 554 Ueki, How to detect eosinophil ETosis (EETosis) and extracellular traps. Allergology 555 International 70, 19-29 (2021). 556 557 25. S. Ueki, Y. Konno, M. Takeda, Y. Moritoki, M. Hirokawa, Y. Matsuwaki, K. Honda, N. Ohta, S. Yamamoto, Y. Takagi, A. Wada, P. F. Weller, Eosinophil extracellular trap cell 558 death-derived DNA traps: Their presence in secretions and functional attributes. J. Allergy 559 Clin. Immunol. 137, 258-267 (2016). 560 26. M. Tanaka, T. Hayashi, S. Morita, The roles of water molecules at the biointerface of 561 medical polymers. Polymer Journal 45, 701-710 (2013). 562 27. T. Hashimoto, S. Ueki, Y. Kamide, Y. Miyabe, M. Fukuchi, Y. Yokoyama, T. Furukawa, 563 N. Azuma, N. Oka, H. Takeuchi, K. Kanno, A. Ishida-Yamamoto, M. Taniguchi, A. 564 Hashiramoto, K. Matsui, Increased Circulating Cell-Free DNA in Eosinophilic 565 Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and 566 Immunothrombosis. Front. Immunol. 12, 801897 (2021). 567 28. T. A. Fuchs, A. Brill, D. Duerschmied, D. Schatzberg, M. Monestier, D. D. Myers, Jr., S. 568 K. Wrobleski, T. W. Wakefield, J. H. Hartwig, D. D. Wagner, Extracellular DNA traps 569 promote thrombosis. Proc. Natl. Acad. Sci. U. S. A. 107, 15880-15885 (2010). 570 29. R. Chen, R. Kang, X. G. Fan, D. Tang, Release and activity of histone in diseases. Cell 571 Death Dis. 5, e1370-e1370 (2014). 572 B. Villeponteau, Heparin increases chromatin accessibility by binding the trypsin-sensitive 573 30. basic residues in histones. Biochem. J. 288 (Pt 3), 953-958 (1992). 574 R. A. Cone, Barrier properties of mucus. Adv Drug Deliv Rev 61, 75-85 (2009). 575 31. 32. S. Ueki, N. Ohta, M. Takeda, Y. Konno, M. Hirokawa, Eosinophilic Otitis Media: the 576 Aftermath of Eosinophil Extracellular Trap Cell Death. Curr. Allergy Asthma Rep. 17, 33 577 (2017). 578 579 33. G. Sollberger, D. O. Tilley, A. Zychlinsky, Neutrophil Extracellular Traps: The Biology of Chromatin Externalization. Dev. Cell 44, 542-553 (2018). 580 H. Nagase, S. Ueki, S. Fujieda, The roles of IL-5 and anti-IL-5 treatment in eosinophilic 34. 581 diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic 582 rhinosinusitis. Allergol Int 69, 178-186 (2020). 583 R. C. Boucher, Muco-Obstructive Lung Diseases. N. Engl. J. Med. 380, 1941-1953 (2019). 35. 584 36. C. R. Esther, M. S. Muhlebach, C. Ehre, D. B. Hill, M. C. Wolfgang, M. Kesimer, K. A. 585 Ramsey, M. R. Markovetz, I. C. Garbarine, M. G. Forest, I. Seim, B. Zorn, C. B. Morrison, 586 M. F. Delion, W. R. Thelin, D. Villalon, J. R. Sabater, L. Turkovic, S. Ranganathan, S. M. 587 Stick, R. C. Boucher, Mucus accumulation in the lungs precedes structural changes and 588 infection in children with cystic fibrosis. Sci. Transl. Med. 11, eaav3488 (2019). doi: 589 10.1126/scitranslmed.aav3488. 590 37. S. Ueki, Y. Miyabe, Y. Yamamoto, M. Fukuchi, M. Hirokawa, L. A. Spencer, P. F. Weller, 591 Charcot-Leyden Crystals in Eosinophilic Inflammation: Active Cytolysis Leads to Crystal 592 Formation. Curr. Allergy. Asthma. Rep. 19, 35 (2019). doi: 10.1007/s11882-019-0868-0. 593 38. V. Papayannopoulos, Neutrophil extracellular traps in immunity and disease. Nat. Rev. 594 Immunol. 18, 134-147 (2018). 595 39. K. K. Malta, C. Palazzi, V. H. Neves, Y. Aguiar, T. P. Silva, R. C. N. Melo, 596 Schistosomiasis Mansoni-Recruited Eosinophils: An Overview in the Granuloma Context. 597 598 *Microorganisms* **10**, (2022). doi: 10.3390/microorganisms10102022.

40. S. Shak, D. J. Capon, R. Hellmiss, S. A. Marsters, C. L. Baker, Recombinant human DNase 599 I reduces the viscosity of cystic fibrosis sputum. Proceedings of the National Academy of 600 Sciences 87, 9188-9192 (1990). 601 602 41. H. J. Fuchs, D. S. Borowitz, D. H. Christiansen, E. M. Morris, M. L. Nash, B. W. Ramsey, B. J. Rosenstein, A. L. Smith, M. E. Wohl, Effect of Aerosolized Recombinant Human 603 DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients 604 with Cystic Fibrosis. N. Engl. J. Med. 331, 637-642 (1994). 605 42. T. Hashimoto, S. Ueki, Y. Kamide, Y. Miyabe, M. Fukuchi, Y. Yokoyama, T. Furukawa, 606 N. Azuma, N. Oka, H. Takeuchi, K. Kanno, A. Ishida-Yamamoto, M. Taniguchi, A. 607 Hashiramoto, K. Matsui, Increased Circulating Cell-Free DNA in Eosinophilic 608 Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and 609 Immunothrombosis. Front. Immunol. 12, 801897 (2021). 610 43. J. Homa, W. Ortmann, E. Kolaczkowska, Conservative Mechanisms of Extracellular Trap 611 Formation by Annelida Eisenia andrei: Serine Protease Activity Requirement. PLoS One 612 11, e0159031 (2016). 613 44. K. C. A. A. Wildhagen, P. García De Frutos, C. P. Reutelingsperger, R. Schrijver, C. 614 Aresté, A. Ortega-Gómez, N. M. Deckers, H. C. Hemker, O. Soehnlein, G. A. F. Nicolaes, 615 Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves 616 survival in sepsis. Blood 123, 1098-1101 (2014). 617 K. R. Acharya, S. J. Ackerman, Eosinophil Granule Proteins: Form and Function. J. Biol. 618 45. Chem. 289, 17406-17415 (2014). 619 D. J. Adamko, Y. Wu, F. Ajamian, R. Ilarraza, R. Mogbel, G. J. Gleich, The effect of 46. 620 cationic charge on release of eosinophil mediators. J. Allergy Clin. Immunol. 122, 383-390, 621 622 390 e381-384 (2008). 47. S. Yuan, M. Hollinger, M. E. Lachowicz-Scroggins, S. C. Kerr, E. M. Dunican, B. M. 623 Daniel, S. Ghosh, S. C. Erzurum, B. Willard, S. L. Hazen, X. Huang, S. D. Carrington, S. 624 Oscarson, J. V. Fahy, Oxidation increases mucin polymer cross-links to stiffen airway 625 mucus gels. Sci. Transl. Med. 7, 276ra227 (2015). 626 48. T. Delemarre, B. S. Bochner, H.-U. Simon, C. Bachert, Rethinking neutrophils and 627 eosinophils in chronic rhinosinusitis. J. Allergy Clin. Immunol. 148, 327-335 (2021). 628 49. S. Ueki, T. Tokunaga, R. C. N. Melo, H. Saito, K. Honda, M. Fukuchi, Y. Konno, M. 629 Takeda, Y. Yamamoto, M. Hirokawa, S. Fujieda, L. A. Spencer, P. F. Weller, 630 Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap 631 cell death. Blood 132, 2183-2187 (2018). 632 50. J. S. Erjefalt, L. Greiff, M. Andersson, E. Matsson, H. Petersen, M. Linden, T. Ansari, P. 633 K. Jeffery, C. G. Persson, Allergen-induced eosinophil cytolysis is a primary mechanism 634 for granule protein release in human upper airways. Am. J. Respir. Crit. Care Med. 160, 635 304-312 (1999). 636 637 51. T. Tokunaga, M. Sakashita, T. Haruna, D. Asaka, S. Takeno, H. Ikeda, T. Nakayama, N. Seki, S. Ito, J. Murata, Y. Sakuma, N. Yoshida, T. Terada, I. Morikura, H. Sakaida, K. 638 Kondo, K. Teraguchi, M. Okano, N. Otori, M. Yoshikawa, K. Hirakawa, S. Haruna, T. 639 Himi, K. Ikeda, J. Ishitoya, Y. Iino, R. Kawata, H. Kawauchi, M. Kobayashi, T. Yamasoba, 640 T. Miwa, M. Urashima, M. Tamari, E. Noguchi, T. Ninomiya, Y. Imoto, T. Morikawa, K. 641 Tomita, T. Takabayashi, S. Fujieda, Novel scoring system and algorithm for classifying 642 643 chronic rhinosinusitis: the JESREC Study. Allergy 70, 995-1003 (2015).

644 645 646 647 648 649 650	52. 53.	<ul> <li>S. Ueki, G. Mahemuti, H. Oyamada, H. Kato, J. Kihara, M. Tanabe, W. Ito, T. Chiba, M. Takeda, H. Kayaba, J. Chihara, Retinoic acids are potent inhibitors of spontaneous human eosinophil apoptosis. <i>J. Immunol.</i> 181, 7689-7698 (2008).</li> <li>S. Ueki, J. Kihara, H. Kato, W. Ito, M. Takeda, Y. Kobayashi, H. Kayaba, J. Chihara, Soluble vascular cell adhesion molecule-1 induces human eosinophil migration. <i>Allergy</i> 64, 718-724 (2009).</li> </ul>
651	Ackno	wledgments: The authors are grateful to Noriko Tan, Satomi Misawa, Nozomi Tanaka, and
652		Chikako Furutani_for their outstanding technical assistance. We thank Satoshi Marumo for
653		helpful discussion and Edanz (https://jp.edanz.com/ac) for editing a draft of this
654		manuscript.
655		
656	Fundi	ng:
657	AstraZ	Zeneca Evidence Connect Externally Sponsored Research (SU)
658	Charita	able Trust Laboratory Medicine Research Foundation of Japan (SU)
659	JSPS H	XAKENHI 15KK0329, 20K08794, 21K08434, and 21K07833 (SU)
660	JSPS I	XAKENHI 17K09993 (MT)
661	JSPS I	XAKENHI 17K17611 (YK).
662	JSPS I	KAKENHI 22K08598 (IM)
663	JSPS H	XAKENHI 17K11356, 25293348, and 20H03832 (TY)
664	Resear	rch Grant on Allergic Disease and Immunology from the Japan Agency for Medical
665		Research and Development JP22ek0410097 (KA)
666	Conse	lho Nacional de Desenvolvimento Científico e Tecnológico 406019 and 309734 (RCNM)

667 Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) (RCNM)

668

## 669 Author contributions:

- 670 Conceptualization: YM, SU
- 671 Methodology: SU, YM, MF, MJ, NT, RCNM
- Investigation: YM, MF, HT, YN, MJ, YM, MA, YK, YM, NT, HS, YS, NO, JT, AM, TY, RCNM,
- 673 SU
- 674 Visualization: YM, YM
- Funding acquisition: SU, MT, YK, TY, KA, IM, RCNM
- 676 Project administration: SU
- 677 Supervision: TH, KA, PFW, SU
- 678 Writing original draft: YM, YN, MF, SU
- 679 Writing review & editing: IM, MJ, TY, RCNM, PFW

680

#### 681 **Competing interests:**

- 682 SU received grants and personal fees from AstraZeneca, GlaxoSmithKline, Sanofi, and grants
- from Novartis, VIB, and Maruho Co. Ltd.
- TY received honoraria from Mitsubishi Tanabe Pharma, Novartis, Sanofi, Taiho and KyorinPharma.

- 686 IM received honoraria from AstraZeneca, Sanofi, Shionogi, Japan Blood Products, Takeda, and
- 687 Meiji pharma.
- 688 KA received honoraria from AstraZeneca, Boehringer Ingelheim Co., Ltd, GlaxoSmithKline plc.,
- 689 Novartis Pharma, and Sanofi.

# 690 Data and materials availability:

All data are available in the main text or the supplementary materials.

# 693 Figure legend

695	Fig. 1. Eosinophil-rich mucus from patients with ECRS showed high CT x-ray attenuation.
696	(A) The microscopic appearance of sectioned mucus in patients with ECRS and non-ECRS
697	(400×, hematoxylin-eosin staining, scale bar=50 $\mu$ m). ( <b>B</b> ) Coronal sinus CT images of
698	patients with ECRS (right) and non-ECRS (left). Red arrowheads indicate high CT
699	attenuation areas in the maxillary sinus. (C) Macroscopic images of surgically-obtained
700	sinus mucus from patients with ECRS and non-ECRS. (D) Comparison of mucus CT
701	values between ECRS and non-ECRS groups (ECRS: $n=40$ ; non-ECRS: $n=26$ , mean $\pm$ SD,
702	**p<0.01, Welch's <i>t</i> test).
703	

705	Fig. 2. Biophysical properties of mucus and their associations with CT density. (A)
706	Measurement of dynamic viscosity against the shear rate of mucus samples using a
707	rotational viscometer. (B) The change in shear viscosity according to the shear rate (orange
708	line: ECRS, n=27; blue line: non-ECRS, n=15). (C) Correlation between shear viscosity at
709	a shear rate of 10 s <sup>-1</sup> and the CT values of each sample (orange: ECRS, n=37; blue:
710	non-ECRS, n=25). Coefficient of correlation, $R^2 \square = 0.45$ ( <b>D</b> ) Measurement of dry weight
711	of the mucus using a thermogravimetric analyzer (TGA). (E) The weight reduction rate of
712	the sample measured using TGA. Samples were gradually heated from 0 to 7.5 minutes and
713	then kept at 100°C. Lines and colored areas indicate mean and $\pm$ SD, respectively (orange:
714	ECRS, n=4; blue: non-ECRS, n=6). (F) Correlation between dry weight and CT values
715	(orange: ECRS, n=4; blue: non-ECRS, n=6). Coefficient of correlation, $R^2 \square = \square 0.69$ (G)
716	Measurement of the contact angle ( $\theta$ ) between water and mucus surface. ( <b>H</b> ) Comparison
717	of contact angle (orange: ECRS, n=40; blue: non-ECRS, n=27, ****p<0.0001,
718	Mann-Whitney U test). (I) Scatter plot shows correlation between contact angle and CT
719	values of the samples (orange: ECRS, n=40; blue: non-ECRS, n=27). Coefficient of
720	correlation, $R^2 \Box = \Box 0.15$ .
721	

724	Fig. 3. Eosinophil- and neutrophil-specific protein contents in mucus. The concentrations of
725	(A) galectin-10, (B) eosinophil-derived neurotoxin (EDN), and (C) myeloperoxidase
726	(MPO) in mucus from patients with ECRS and non-ECRS (ECRS, n=37; non-ECRS,
727	n=25; mean ± SE, * p<0.05 ** p<0.01 *** p<0.001, Welch's <i>t</i> test.).
728	

730	Fig. 4. The characteristics of cell aggregates. (A) Preparation of aggEETs and aggNETs.
731	Isolated human eosinophils and neutrophils were stimulated with PMA to induce ETosis.
732	After plate shaking, aggregated cells were collected. (B) Macroscopic images of aggEETs
733	and aggNETs. (C) Microscopic appearance of sectioned aggEETs and aggNETs ( $400 \times$ ,
734	hematoxylin-eosin staining, scale bar: 50 $\mu$ m). ( <b>D</b> ) Comparison of CT values between
735	aggEETs and aggNETs (n=3, repeated measures, Welch's test, ****p<0.0001). (E) The
736	change in shear viscosity of cell aggregates according to shear rate (orange line: aggEETs,
737	n=3; blue line: aggNETs, n=3). (F) Mass reduction rate of cell aggregates using TGA
738	(orange: aggEETs, n=6; blue: aggNETs, n=6). Lines and colored area indicate mean and $\pm$
739	SD, respectively. (G) Comparison of dry weights (aggEETs, n=6; aggNETs, n=6; *p<0.05,
740	Welch's test). (H) Comparison of contact angles (aggEETs, n=14; aggNETs, n=14;
741	****p<0.0001, Welch's test).
742	
743	

745	Fig. 5. The effect of heparin and DNase on EETs. (A) Scanning electron microscope (SEM)
746	images of non-treated control and heparin treated EETs (Scale bar=1 $\mu$ m). The EETs
747	consist of smooth stretch and globular domains (red arrowheads). (B) Transmission
748	electron microscope images of non-treated or heparin treated EETs. White arrowheads
749	indicate globular domain. (C) Comparison of fiber diameters of extracellular traps assessed
750	by SEM (n=200, ****p<0.0001, Welch's <i>t</i> test). ( <b>D</b> ) Measurement of free dsDNA detected
751	in the culture supernatant briefly treated with heparin and/or DNase 1 ( $n=4$ , **** $p<0.0001$ ,
752	Tukey's multiple comparisons test).
753	

## 

755	Fig. 6. Heparin enhances the effect of DNase on aggEETs. (A) Morphological change in
756	aggEETs under the effect of DNase and/or heparin was assessed by SYTOX DNA dye
757	using inverted fluorescence microscopy (scale bar=200 $\mu$ m, ×20 objective). (B) The cell
758	aggregates were treated with DNase and/or heparin for 2 hours and shear viscosity was
759	assessed by a rotational rheometer (n=3 for each group, mean $\pm$ SD). (C) Comparison of
760	contact angle of cell aggregates treated with DNase and/or heparin (n=3, $p<0.05$ ,
761	**p<0.01, ***p<0.001, Kruskal-Wallis test: p<0.01).

## 

764	Fig. 7. The effect of heparin on mucus in patients with ECRS. (A) The change in shear
765	viscosity of mucus obtained from patients with ECRS (n=7 for each group, mean $\pm$ SD).
766	(B) Comparison of contact angle of mucus treated with DNase and/or heparin (each group:
767	n=4, ****p<0.0001, Kruskal-Wallis test: p<0.01). (C) Illustration of the effects of heparin
768	on aggEETs in mucus. Airway mucus contains large amounts of aggEETs that contribute
769	to viscosity. Heparin relaxed their condensed chromatin structure and enhanced the effect
770	of DNase.

	Galectin-10	EDN	MPO
Shear viscosity	r = 0.74*	r = 0.48*	r = -0.25
Dry weight	r = 0.74*	r = 0.25	r = -0.10
Contact angle	r = 0.58*	r = 0.37*	r = -0.28*
CT value	r = 0.49**	r = 0.25*	r = 0.21*

# 772 Table 1. Correlations between eosinophil- or neutrophil-specific proteins in mucus and its

biophysical properties. \*p<0.05 \*\*\*p<0.001, Spearman's rank correlation coefficient

Figure 1

D







Figure 3



## Table 1. Correlation between eosinophil-specific proteins and physical properties

Correlation coefficients		
galectin-10	EDN	MPO
r=0.74 *	r=0.48 *	r=-0.23
r=0.74 *	r=0.25	r=-0.10
r=0.58 *	r=0.37 *	r=-0.28 *
r=0.49 ***	r=0.25 *	r=0.21
	Correl galectin-10 r=0.74 * r=0.74 * r=0.58 * r=0.49 ***	Correlation coefficient         galectin-10       EDN         r=0.74*       r=0.48*         r=0.74*       r=0.25         r=0.58*       r=0.37*         r=0.49***       r=0.25*

## Figure 4





Figure 6



